INTRODUCTION {#s1}
============

Cancer is one of the leading causes of morbidity and mortality worldwide today \[[@R1]\]. Although encouraging progress in treatment for cancer has been achieved, the 5-year survival rate remains low and the majority of patients die due to relapse and metastases \[[@R2]\]. The ideal prognostic marker helps predict the tumor prognosis, which is of great significance for designing reasonable plans for disease surveillance and treatment. Recently, researchers focused on tumor biomarkers and have identified numerous potential biomarkers for tumor prognosis and treatment \[[@R3]--[@R4]\]. However, it is urgently needed for the sensitive and specific biomarkers for prognosis of patients with cancers.

Long noncoding RNAs (lncRNAs) are nonprotein-coding transcripts with length of 200 nucleotides, which have been dismissed as transcriptional "noise" in the past decade \[[@R5], [@R6]\]. Nowadays, accumulating evidence shows that lncRNAs play tremendous roles in cell proliferation, differentiation, apoptosis and transformation \[[@R7]--[@R9]\]. Clinicopathologic studies have suggested that lncRNAs are related to prognosis and metastasis of various tumors, therefore, they may be sensitive and specific biomarkers for the prediction of cancer progression and prognosis \[[@R10]--[@R13]\].

Zinc finger antisense 1 (ZFAS1) is a newly identified lncRNA, which has attracted widespread attention recently. Aberrant high expression of ZFAS1 was reported in a series of human cancers, including hepatocellular carcinoma \[[@R14]\], gastric cancer \[[@R15]--[@R17]\], melanoma \[[@R18]\], lung cancer \[[@R19]\], glioma \[[@R20]\] and colorectal cancer \[[@R21]--[@R23]\]. It was observed that high ZFAS1 expression was associated with metastasis and prognosis, thus ZFAS1 may be a potential biomarker for prognosis. This current meta-analysis was performed to explore the correlation of ZFAS1 expression with clinical outcome of cancer patients, and further determine whether ZFAS1 could serve as an effective biomarker for metastasis and prognosis.

MATERIALS AND METHODS {#s2}
=====================

Search strategy {#s2_1}
---------------

We searched for potentially eligible literatures published up to June 2017 through PubMed, Embase, Web of Science, Chinese Wan Fang and CNKI database for the meta-analysis. The search strategy used both MeSH terms and free-text words to increase sensitivity. The keywords for the search were as follows: "ZFAS1 and cancer", "long non-coding RNA ZFAS1", "lncRNA ZFAS1", "ZFAS1". Articles were limited to English-language and Chinese-language publications. Meanwhile, reference lists of relevant articles were also reviewed to identify potentially eligible papers.

Inclusion and exclusion criteria {#s2_2}
--------------------------------

In this meta-analysis, eligible studies had to meet the following standards: 1) studies with a cohort design, 2) studies investigating the correlation between ZFAS1 expression and cancer patients, 3) studies in which ZFAS1 expression in primary tumor tissues was measured by real-time quantitative reverse transcription PCR (qRT-PCR), 4) studies with sufficient original data for calculating odd ratios (ORs), hazard ratios (HRs) and their 95% confidence interval (95% CI). If an article only provided survival curves without offering HR and 95% CI directly, appropriate data were extracted from the survival curves using Engauge Digitizer 4.1 software, and logHR and selogHR were calculated according to Tierney *et al*. \[[@R24]\]. The following criteria were used to exclude studies: 1) duplicate publications; 2) studies of case reports, letters, and reviews; 3) studies without usable data.

Date extraction {#s2_3}
---------------

Two investigators extracted the data independently through a same standard. Any disagreement was consulted with a third investigator. The following details were extracted: first author, publication year, country of origin, cancer type, detection method of ZFAS1, total number of patients, number of high ZFAS1 expression group and low expression group, number of patients with LNM, the HR and the corresponding 95% confidence interval (CI) for overall survival (OS).

Statistical analysis {#s2_4}
--------------------

ORs and 95% CI were used to evaluate the relationship between ZFAS1 expression and LNM, and HRs and 95% CI were used to assess the effect of ZFAS1 expression on the survival. In order to evaluate the heterogeneity of the included studies, Cochrane *Q*-test and I^2^ statistics were performed by using Stata 12.0 Software (Stata, College Station, TX, USA). If there was a significantly statistical heterogeneity (I^2^ ≥ 50% or *P* ≤ 0.05) among the studies, we used the random-effects model to analyze the results, and performed subgroup and sensitivity analysis to dissect the heterogeneity. If the heterogeneity was absent, the fixed-effects model was applied to this meta-analysis. In addition, the Stata 12.0 Software was used to evaluate the sensitivity of the studies. Publication bias was evaluated by Begg\'s test and Egger\'s test, *P* \< 0.05 was considered statistically significant. Forest plots were used to dispaly the meta-analysis results, and Begg\'s funnel plots were used to show publication bias.

The method reported by Wacholder et al. \[[@R25]\] was used to analyze the false positive report probability (FPRP) and statistical power of each significant correlation. A prior probability of 0.1 was set to detect an OR of 0.67/1.50 (protective/risk effects). When the FPR*P* value was lower than 0.2, the correlation was noteworthy. Statistical power and FPR *P* value were calculated using the Excel spreadsheet provided by Wacholder et al. \[[@R25]\].

RESULTS {#s3}
=======

Characteristics of eligible studies {#s3_1}
-----------------------------------

A flow diagram of literature search process was presented in Figure [1](#F1){ref-type="fig"}. After searching PubMed, Embase, Web of Science, Chinese Wan Fang and CNKI database, we selected twelve studies ranging 2015 to 2017 based on the inclusion criteria, and these studies were all from People\'s Republic of China. Seven different types of cancer were evaluated in the meta-analysis, with one case of non-small cell lung cancer (NSCLC), three cases of gastric cancer (GC), three cases of colorectal cancer (CRC), one case of hepatocellular carcinoma (HCC), two case of glioma, one case of melanoma and one case of ovarian cancer (OC).

![Flowchart presenting the steps of literature search and selection](oncotarget-08-84497-g001){#F1}

Table [1](#T1){ref-type="table"} summarized the main characteristics of the included twelve studies enrolling 1075 participants, with the mean patient sample size of 80.5 (range 54--173). In these studies, ZFAS1 expression in tumor tissues was determined by qRT-PCR. All studies comprised a high ZFAS1 expression group and a low ZFAS1 expression group. Nine studies investigated the association between ZFAS1 expression and OS, and nine studies assessed the association between ZFAS1 expression and LNM. HRs and 95% CIs were directly extracted from five studies, and calculated by survival curves in five studies. ORs and 95% CIs were directly extracted from nine studies.

###### Characteristics of ZFAS1 studies included in the meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First auhor    Year   Country   Cancer Type   Sample size   ZFAS1 expression   Detection method   Cut-off value   Outcome   HR estimate   NOS\     IF value                        
                                                                                                                                            score                                    
  -------------- ------ --------- ------------- ------------- ------------------ ------------------ --------------- --------- ------------- -------- ---------- ---------------- --- -------
  Wang et al.    2016   China     CRC           159           50                 29                 38              42        qRT-PCR       Median   OS         Reported         7   1.543

  Tian et al.    2016   China     NSCLC         173           58                 27                 34              54        qRT-PCR       NA       OS         Reported         6   1.778

  Nie et al.     2016   China     GC            54            12                 15                 16              11        qRT-PCR       Median   OS         Survival curve   8   5.168

  Pan et al.     2017   China     GC            94            48                 10                 19              17        qRT-PCR       NA       \-         \-               6   3.502

  Fang et al.    2016   China     CC            73            15                 21                 6               31        qRT-PCR       NA       OS         Survival curve   7   3.452

  Lv et al.      2017   China     glioma        69            \-                 \-                 \-              \-        qRT-PCR       Median   OS         Reported         6   3.650

  Li et al.      2015   China     HCC           88            \-                 \-                 \-              \-        qRT-PCR       Median   OS         Survival curve   7   9.122

  Wu et al.      2016   China     CRC           67            12                 22                 15              18        qRT-PCR       Median   \-         \-               6   NA

  Wei et al.     2017   China     melanoma      88            38                 8                  22              20        qRT-PCR       Median   OS         Reported         8   1.706

  Zhang et al.   2016   China     GC            104           25                 27                 8               44        qRT-PCR       Median   OS         Reported         8   1.706

  Xia et al.     2017   China     OC            60            16                 14                 4               26        qRT-PCR       NA       OS         Survival curve   7   5.168

  Gao et al.     2017   China     glioma        46            \-                 \-                 \-              \-        qRT-PCR       NA       OS         Survival curve   6   1.971
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Relationship between ZFAS1 and OS {#s3_2}
---------------------------------

Nine studies consisting of 841 patients reported the OS according to levels of ZFAS1 expression, and the median sample size was 88 (range 54--173) in this meta-analysis. Given that there was no heterogeneity across these studies (I^2^ = 0.0%, *P* = 0.964; Figure [2](#F2){ref-type="fig"}), the fixed-effects model was applied to estimate the pooled HRs and the respective 95% CIs. As shown in Figure [2](#F2){ref-type="fig"}, our results revealed that high ZFAS1 expression predicted poor OS in various cancers (pooled HR: 1.94, 95% CI: 1.41--2.47, *P* \< 0.001; fixed-effect).

![Forest plot for the association between ZFAS1 expression with OS](oncotarget-08-84497-g002){#F2}

Relationship between ZFAS1 and LNM {#s3_3}
----------------------------------

Nine studies reported the number of patients with LNM in a total of 872 individuals. The median sample size was 88 (range 54--173). As shown in Figure [3](#F3){ref-type="fig"}, the random-effects model was adopted for the significant heterogeneity (I^2^ = 67.1%, *P* = 0.002). Our results revealed that high ZFAS1 expression was significantly associated with LNM (pooled OR: 2.60, 95% CI: 1.54--4.42, *P* \< 0.001, random-effects). Because of the significant heterogeneity between studies, subgroups were analyzed based on the tumor type, sample size, quality score and publication year (Table [2](#T2){ref-type="table"}). Our data revealed that high ZFAS1 expression was related to high incidence of LNM in subgroups of sample size more than 88 (OR: 3.16, 95% CI: 2.06--4.86, *P* \< 0.001), non-digestive system malignancies (OR: 4.05, 95% CI: 2.49--6.60, *P* \< 0.001), studies reported in 2017 (OR: 4.86, 95% CI: 2.67--8.84, *P* \< 0.001) without significant heterogeneity. In addition, we further performed meta-regression by the covariates including tumor type, sample size, quality score and publication year. As shown in Table [2](#T2){ref-type="table"} and Figure [4](#F4){ref-type="fig"}, those factors did not result in the inter-study eterogeneity.

![Forest plot for the association between ZFAS1 expression with LNM](oncotarget-08-84497-g003){#F3}

![(**A**) Based on tumor type ; (**B**) Based on sample size; (**C**) Based on NOS score; (**D**) Based on publication year.](oncotarget-08-84497-g004){#F4}

###### Results of subgroup analysis of increased ZFAS1 expression and LNM in various carcinomas

  Stratified analysis    No. of studies   No. of patients   Heterogeneity   Pooled OR (95% CI)   *P*-value           Meta-regression *P* value   
  ---------------------- ---------------- ----------------- --------------- -------------------- ------------------- --------------------------- -------
  Tumor type                                                                                                                                     0.144
   Digestive system      6                551               72.3            0.003                1.98 (0.97--4.04)   0.062                       
  Non-digestive system   3                321               0               0.555                4.05 (2.49--6.60)   \< 0.001                    
  Sample size                                                                                                                                    0.825
   Number ≤ 88           4                342               77.9            0.001                2.07 (0.74--5.74)   0.164                       
   Number \> 88          5                530               23.2            0.272                3.16 (2.06--4.86)   \< 0.001                    
  NOS score                                                                                                                                      0.610
   ≤ 6                   4                407               59.7            0.059                1.51 (1.06--2.16)   0.023                       
   \> 6                  5                465               75.3            0.003                1.62 (1.06--2.48)   0.027                       
  Publication year                                                                                                                               0.069
   2016                  6                630               72.6            0.003                1.94 (1.00--3.78)   0.050                       
   2017                  3                242               0.0             0.002                4.86 (2.67--8.84)   \< 0.001                    

![Sensitivity analyses of the studies\
(**A**) Overall survival; (**B**) Lymph node metastasis.](oncotarget-08-84497-g005){#F5}

FPRP test {#s3_4}
---------

The significant associations were investigated by using the FPRP test. For a prior probability of 0.1, high ZFAS1 expression was associated with LNM in subgroup of nondigestive system malignancies (FPRP \< 0.001), sample size more than 88 (FPRP \< 0.001) and studies reported in 2017 (FPRP \< 0.001). FPR*P* value and statistical power were shown in Table [3](#T3){ref-type="table"}.

###### False-positive report probability values for associations between increased ZFAS1 expression and LNM in various carcinomas

  Stratified analysis    Pooled OR (95% CI)   *P*-value   Statistical Power   Prior probability                                    
  ---------------------- -------------------- ----------- ------------------- ------------------- ---------- ---------- ---------- ----------
  Tumor type                                                                                                                       
   Digestive system      1.98 (0.97--4.04)    0.062       0.564               0.243               0.491      0.914      0.991      0.999
  Non-digestive system   4.05 (2.49--6.60)    \< 0.001    0.520               \< 0.001            \< 0.001   \< 0.001   \< 0.001   \< 0.001
  Sample size                                                                                                                      
   Number ≤ 88           2.07 (0.74--5.74)    0.164       0.511               0.471               0.727      0.967      0.997      1.000
   Number \> 88          3.16 (2.06--4.86)    \< 0.001    0.523               \< 0.001            \< 0.001   \< 0.001   \< 0.001   0.003
  NOS score                                                                                                                        
   ≤ 6                   1.51 (1.06--2.16)    0.023       0.485               0.129               0.308      0.831      0.980      0.998
   \> 6                  1.62 (1.06--2.48)    0.027       0.362               0.180               0.396      0.878      0.986      0.999
  Publication year                                                                                                                 
   2016                  1.94 (1.00--3.78)    0.050       0.536               0.224               0.464      0.905      0.990      0.999
   2017                  4.86 (2.67--8.84)    \< 0.001    0.537               \< 0.001            \< 0.001   \< 0.001   \< 0.001   0.004

Sensitivity analysis and publication bias {#s3_5}
-----------------------------------------

Sensitivity analysis was performed by using Stata12.0 software to assess whether the individual study affected the overall results. The results showed that individual study had little influence on our final results (Figure [5](#F5){ref-type="fig"}), thus our results were relatively stable and credible. We used both Begg\'s test and Egger\'s test to evaluate publication bias. Begg\'s funnel plot with pseudo 95% CIs was provided. Our data didn\'t revealed publication bias across the studies, including meta-analysis of the association of ZFAS1 expression with OS (Begg\'s test:Pr\>\|Z\| = 0.602; Egger\'s test: P\>\|t\| = 0.459) and LNM (Begg\'s test: Pr \>\|Z\| = 0.917; Egger\'s test:P \>\|t\| = 0.949) (Figure [6](#F6){ref-type="fig"}).

![Begg\'s test for publication bias\
(**A**) Overall survival; (**B**) Lymph node metastasis. Abbreviations: SE, standard error.](oncotarget-08-84497-g006){#F6}

DISCUSSION {#s4}
==========

Recent studies indicated that numberous lncRNAs such as nuclear paraspeckle assembly transcript 1 (NEAT1), cyclin D2 antisense RNA 1 (CCND2-AS1), taurine-upregulated gene 1 (TUG1) and HOX transcript antisense RNA (HOTAIR) were overexpressed in tumors, and involved in tumor occurrence and progression \[[@R26]--[@R29]\]. As potential new molecular biomarkers, differential levels of lncRNAs or cancer-specific lncRNA profiles may be used for the prediction of cancer prognosis.

ZFAS1, located at chromosomal band 20q13.13, was first reported dysregulated in breast cancer, suggesting a role of ZFAS1 in this type of cancer \[[@R30]\]. Subsequently, ZFAS1 was confirmed involved in a series of human tumors. For instance, Li *et al*. showed that ZFAS1 was amplified in HCC, and promoted HCC cell invasion and migration by positively regulating ZEB1, MMP14 and MMP16 \[[@R14]\]. Nie *et al*. found that ZFAS1 might act as a oncogene in GC by repressing KLF2 and NKD2 expression \[[@R15]\]. Moreover, Wang *et al*. showed that ZFAS1 was upregulated in CRC, which prompted metastasis of CRC \[[@R22]\]. Recently, studies indicated consistent results about the relationship between high ZFAS1 expression and poorer prognosis in CRC, GC, HCC, glioma, melanoma and NSCLC \[[@R14], [@R15], [@R17], [@R18], [@R19], [@R20], [@R22]\]. However, there is controversy about the relationship between ZFAS1 expression and LNM in various cancers. Some studies indicated that high ZFAS1 expression was associated with LNM \[[@R16], [@R17], [@R18], [@R19], [@R21], [@R22]\], While others showed no significant associated between elevated ZFAS1 levels and LNM \[[@R15], [@R23]\]. These findings suggest that ZFAS1 may be a promising indicator of prognosis in human cancers, but further confirmation by extensive analysis is required.

In our meta-analysis, we assessed the association of ZFAS1 expression with metastasis and prognostic outcome. From the available studies, we found that high ZFAS1 expression was associated with poor OS in different types of cancers without significant heterogeneity, suggesting that ZFAS1 may serve as a reliable molecular marker for poor prognosis in various cancers. In addition, we found there was a significant association between ZFAS1 expression and LNM, but with heterogeneity. Therefore, we performed subgroup analysis to precisely assess the association of ZFAS1 with LNM. Subgroup analyses showed a remarkable decrease in the heterogeneity of LNM in subgroups of "sample size more than 88", "non-digestive system malignancies' and "studies reported in 2017", suggesting that "tumor type" , "sample size" and "publication year " may be as sources of heterogeneity. Moreover, data from subgroup analysis showed that high ZFAS1 expression was related to high incidence of LNM in the subgroup of sample size \> 88, non-digestive system malignancies and studies reported in 2017, which further strengthened the pooled result. To make our results more reliable, we performed FPRP test, and found that the correlation of high ZFAS1 expression with LNM in subgroup of nondigestive system malignancies, sample size \> 88 and studies reported in 2017 all passed the FPRP test, indicating these associations were reliable.

Taken together, our meta-analysis results indicate that ZFAS1 may act as a novel biomarker in predicting the clinical outcome of cancer patients. Further studies exploring the relationship between LNM and ZFAS1 expression are required to verify its clinical prognostic value in human cancers.

There are some limitations in our analysis. First, the number of patients and types of cancers included are relatively small. Second, studies included in the meta-analysis all come from People\'s Republic of China, for this reason, our results may just represent the cases of Chinese cancer patients. Third, positive results can be published more easily than negative ones, which may lead to larvaceous publication bias. Fourth, this meta-analysis is a retrospective analysis, which may limit the conclusion due to selection bias. Fifth, the quality of studies included in the meta-analysis was uneven and thus limit the precision and generalizability of the pooled estimates. Finally, these studies lack a unified criterion for high ZFAS1 expression. Therefore, larger-scale, multicenter, and higher-quality studies are required to confirm our findings in the future.
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